Research Article
Body Composition in Crohn’s Disease and Ulcerative Colitis: Correlation with Disease Severity and Duration
Table 1
Baseline characteristics of patients of ulcerative colitis and Crohn’s disease.
| | UC | CD | value |
| Parameters | | | |
| Age in years, mean ± SD | 33.2 ± 11.2 | 41.2 ± 15.8 | 0.01 |
| Sex, male (, %) | 36 (67.9%) | 32 (72.7%) | 0.61 |
| Duration of symptoms (months), median | 24 (12–48) | 36 (18–105) | 0.15 |
| Haemoglobin, g/dL, mean ± SD | 11.8 ± 2.5 | 10.8 ± 2.9 | 0.02 |
| Albumin, g/dL, mean ± SD | 4.2 ± 0.5 | 4.0 ± 0.8 | 0.11 |
| Extent/location of disease | E1: 3 (5.6%) E2: 35 (66%) E3: 15 (28.3%) | L1: 21 (47.7%) | | L2: 10 (22.7%) | L3: 11 (25%) | L4: 10 (22.7%) |
| Disease behavior | | B1: 21 (45.7%) | | B2: 23 (50%) | B3: 2 (4.3%) |
| Treatment received |
| 5-ASA | 53 (100) | 10 (22.7) | |
| Steroids | 16 (30.2) | 29 (65.9) | |
| Immunomodulators | 17 (32.1) | 26 (40.9) | |
| Biologics | 0 (0) | 0 (0) | |
|
|
E1: proctitis; E2: left sided colitis; E3: pancolitis; L1: terminal ileum ± caecum; L2: colonic; L3: ileocolonic; L4: proximal small intestine; B1: inflammatory; B2: stricturing; B3: penetrating; p: perianal; ASA: aminosalicylic acid.
|